Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials

M. Kripp, 1 K. Horisberger, 2 S. Mai, 3 P. Kienle, 2 T. Gaiser, 4 S. Post, 2 F. Wenz, 3 K. Merx, 1 and R.-D. Hofheinz 5

1III. Medizinische Klinik, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
2Chirurgische Klinik, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
3Klinik für Strahlentherapie und Radioonkologie, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
4Pathologisches Institut, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
5Interdisziplinäres Tumorzentrum, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

Correspondence should be addressed to M. Kripp; melanie.kripp@medma.uni-heidelberg.de

Received 15 December 2014; Accepted 3 March 2015

Academic Editor: Eiji Sakai

Copyright © 2015 M. Kripp et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The addition of cetuximab to radiochemotherapy (RCT) failed to improve complete response rates in locally advanced rectal cancer (LARC). We report the long-term results in patients treated within two sequential clinical trials.

Methods. Patients receiving neoadjuvant RCT using capecitabine and irinotecan (CapIri) within a phase I/II trial or CapIri + cetuximab within a phase II trial were evaluated for analysis of disease-free survival (DFS) and overall survival (OS). KRAS exon 2 mutational status had been analyzed in patients receiving cetuximab.

Results. 37 patients from the CapIri trial and 49 patients from the CapIri-cetuximab treatment group were evaluable. Median follow-up time was 75.2 months. The 5-year DFS rate was 82% (CapIri) and 79% (CapIri-cetuximab) ($P = 0.62$). The median OS was 127.4 months. 5-year OS was 73% for both groups (CapIri and CapIri-cetuximab) ($P = 0.61$). No significant difference in DFS ($P = 0.86$) or OS ($P = 0.39$) was noticed between patients receiving CapIri and those receiving CapIri-cetuximab with KRAS wild-type tumors.

Conclusions. As the addition of cetuximab did not improve neither DFS nor OS it should not play a role in the perioperative treatment of patients with LARC, not even of patients with (K)RAS WT tumors.

1. Introduction

Neoadjuvant radiochemotherapy (RCT) with fluoropyrimidines followed by total mesorectal excision (TME) is a standard therapy for locally advanced rectal cancer (LARC) [1]. Epidermal growth factor receptor (EGFR) is overexpressed in 50–70% of primary rectal cancers [2] and is related to decreased pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS) [3, 4]. Thus, several studies sought to investigate the efficacy of combined treatment regimens using targeted agents directed against EGFR in conjunction with RCT [5–11].

Cetuximab is a chimeric anti-EGFR monoclonal antibody approved for the treatment of metastatic colorectal cancer. In patients with metastatic colorectal cancer it has been demonstrated that the benefit is limited to patients with wild-type (WT) (K)RAS tumors [12, 13]. However, the addition of anti-EGFR antibodies to RCT failed to improve pathological complete response rates in patients with LARC [6–10, 14–18]. Only few randomized trials have been reported so
far. EXPERT-C, a multicenter randomized phase II trial, investigated the addition of cetuximab to preoperative induction chemotherapy and RCT in 165 patients with high-risk rectal cancer. In 149 patients with KRAS/BRAF WT tumors the addition of cetuximab to capecitabine and oxaliplatin (CapOx) led to a significant increase in radiologic response rates but the primary endpoint (increasing pCR rate) was missed. Regarding overall survival, a significant benefit for patients in the cetuximab group was noticed in the initial study report [11]. However, after a median follow-up of 63.8 months the improvement of overall survival in RAS WT patients was still clinically meaningful but did not retain statistical significance (5-year overall survival CapOx-Cetuximab 83.8% and CapOx 70.0%; \( P = 0.20 \)) [19].

Another randomized phase II trial evaluated the addition of the fully human anti-EGFR antibody panitumumab to a capecitabine-based RCT regimen as neoadjuvant treatment for KRAS WT LARC in 68 patients staged cT3/4 or N+. The primary endpoint was the rate of pathological near-complete or complete remissions applying Dworak regression grading [20]. While the pCR rate was not increased by the addition of panitumumab, the rate of near-complete plus complete remissions was substantially higher (53% versus 32%). Long-term data have not been reported [21].

In view of the paucity of randomized studies and few follow-up data, we herein report a long-term analysis of study patients receiving either capecitabine/irinotecan (CapIri) or CapIri-cetuximab based RCT for LARC within two sequential clinical trials using comparable inclusion criteria.

### 2. Material and Methods

#### 2.1. Patients
In the current analysis we evaluated long-term results of patients receiving neoadjuvant RCT using CapIri (within a phase I/II trial) or CapIri + cetuximab (within a phase II trial). These trials were conducted on a monocentric basis at the Departments of Oncology, Radiotherapy and Radiooncology, and Surgery at the University Hospital of Mannheim, University of Heidelberg, Germany. The trials have been reported in detail previously [9, 22, 23]. Briefly, patients with LARC were scheduled to receive CapIri (i.e., irinotecan 50 mg/m\(^2\) on days 1, 8, 15, 22, and 29 in combination with capecitabine 500–625 mg/m\(^2\) b.i.d. on days 1 through 38) or CapIri-cetuximab ( cetuximab 400 mg/m\(^2\) on day 1 and 250 mg/m\(^2\) on days 8, 15, 22, and 29 in combination with irinotecan 40 mg/m\(^2\) on days 1, 8, 15, 22, and 29 and capecitabine 500 mg/m\(^2\) b.i.d. on days 1 through 38). Patients included in both trials with local tumor relapse or metastases (even if deemed resectable) were excluded for the present analysis. Surgery was scheduled to take place 4–6 weeks after termination of RCT.

All patients included in the current analysis had histologically confirmed rectal cancer staged with endoscopic ultrasound as cT3-T4 or N+ tumors. MRI was not used as an inclusion criterion. Distant metastases had been excluded with CT scan. Further patient eligibility criteria comprised Eastern Cooperative Oncology Group performance status \(\leq 2\), age \(\geq 18\) years, adequate bone marrow (leukocyte count > 3000/μL and platelet count > 100,000/μL), and sufficient renal (serum creatinine \(\leq 1.4\) mg/dL or creatinine clearance > 60 mL/min) and hepatic (bilirubin \(\leq 2\) mg/dL) function. Patients were excluded if they had other forms of cancer or had known hypersensitivity to 5-FU (5-fluorouracil), irinotecan, or cetuximab.

All studies were conducted according to the Declaration of Helsinki. The protocols were approved by the local ethical committee. Written informed consent was obtained from each patient before study entry.

Resection specimens were pathologically analyzed and pCR was defined as complete absence of tumor cells.

KRAS exon 2 mutational status had been analyzed in patients having received CapIri and cetuximab using formalin-fixed, paraffin-embedded tumor tissue obtained prior to the start of RCT [24]. Briefly, for analysis of KRAS mutations, microdissection of tumor tissue was carried out, and DNA (deoxyribonucleic acid) was subjected to (semi)nested PCR (polymerase chain reaction) amplification of exon 2 of the KRAS gene containing codons 12 and 13. Further mutation analyses (KRAS exons 3 and 4 and NRAS exons 2–4) were not performed because written informed consent had been given only for KRAS exon 2 status.

#### 2.2. Statistical Analyses
Disease-free survival was defined as time to local recurrence, metastases, or death whichever occurred first, and overall survival was calculated as the time from start of treatment until death. Time-to-event data were calculated using the Kaplan-Meier method. Comparisons between the groups were performed using the log-rank (Mantel-Cox) test.

To compare clinical and pathological parameters, including age, gender, T/N level downstaging, and pCR rates we used the unpaired \( t \)-test, Fisher’s exact test, and Chi square, respectively. A 2-sided \( P \) value of \( P \leq 0.05 \) was considered significant.

Statistical analyses and figures were performed with GraphPad Prism 5.

### 3. Results

#### 3.1. Patients’ and Tumor Characteristics
A total of 93 patients were included in both trials between May 2002 and February 2008: \( n = 43 \) patients were treated with CapIri and \( n = 50 \) patients with CapIri and cetuximab. A total of \( n = 7 \) patients had to be excluded for the current analysis because they had been treated within these trials with distant metastases or a local relapse (\( n = 6 \) were excluded from the CapIri cohort and \( n = 1 \) from the CapIri-cetuximab cohort, resp.). In summary, \( n = 37 \) patients from the CapIri trial and \( n = 49 \) patients from the CapIri-cetuximab treatment group were evaluable for the current analysis.

Both groups did not differ from each other regarding gender, age, clinical T and N, and UICC (Union internationale contre le cancer) status. Patients’ tumor characteristics are depicted in Table 1.

In 45 out of 49 patients treated with CapIri and cetuximab analysis of KRAS mutations could be done. Of these, 32
Table 1: Characteristics of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/- cetuximab based chemoradiotherapy as preoperative treatment.

|                                      | Capecitabine/irinotecan (n = 37) | Capecitabine/irinotecan + cetuximab (n = 49) | P value |
|--------------------------------------|----------------------------------|---------------------------------------------|---------|
| Gender, n (%)                        |                                  |                                             |         |
| Male                                 | 29 (78)                          | 33 (67)                                     |         |
| Female                               | 8 (22)                           | 16 (33)                                     |         |
| Fisher’s exact test                  |                                  |                                             | 0.33    |
| Age (years); median (range)          | 60 (34–82)                       | 57 (33–80)                                  | 0.79    |
| Unpaired t-test                      |                                  |                                             |         |
| Clinical TNM stage, n (%)            |                                  |                                             |         |
| cT1                                  | 0 (0)                            | 0 (0)                                       |         |
| cT2                                  | 4 (11)                           | 9 (18)                                      |         |
| cT3                                  | 28 (76)                          | 36 (73)                                     |         |
| cT4                                  | 4 (11)                           | 4 (8)                                       |         |
| cTx                                  | 1 (3)                            | 0 (0)                                       |         |
| Chi square                           |                                  |                                             | 0.62    |
| cN−                                  | 6 (16)                           | 15 (31)                                     |         |
| cN+                                  | 31 (84)                          | 34 (69)                                     |         |
| Fisher’s exact test                  |                                  |                                             | 0.14    |
| Tumor distance from anal verge (cm); median (range) | 6 (2–13) | 7 (0–13) | 0.77 |
| Unpaired t-test                      |                                  |                                             |         |
| KRAS status, n (%)                   |                                  |                                             |         |
| KRAS wild-type                       | n.a.                             | 32 (65)                                     |         |
| KRAS mutation                        | n.a.                             | 13 (27)                                     |         |
| KRAS unknown                         | n.a.                             | 4 (8)                                       |         |
| Surgical technique                   |                                  |                                             |         |
| Low anterior resection               | 31                               | 41                                          |         |
| Abdominoperineal resection           | 6                                | 7                                           |         |
| Hartmann’s operation                 | 0                                | 1                                           |         |
| Chi square                           |                                  |                                             | 0.67    |
| Time to resection (days), median (range) | 39 (21–79) | 38 (21–67) | 0.94 |
| Unpaired t-test                      |                                  |                                             |         |

n.a.: not applicable.

patients (71.1%) were KRAS WT, and 13 patients (28.9%) had tumors harboring KRAS mutations.

3.2. Pathohistological Analysis of Resection Specimen. A total of 11 patients achieved a pCR, seven (19%) with CapIri and four (8%) with CapIri-cetuximab. The difference was not significant (n.s.).

A T-downstaging (defined as ypT0-2, N0) occurred in 30 patients (24% with CapIri and 43% with CapIri-cetuximab; n.s.). A nodal negative tumor upon resection occurred in 59 patients (62% with CapIri and 73% with CapIri-cetuximab; n.s.). Data are shown in Table 2.

3.3. Disease-Free and Overall Survival. All patients were followed up for survival time; no patient was lost to follow-up.

At the time of analysis, a total of 30 patients had died (34.9%). Median follow-up time for all patients was 75.2 months. Follow-up data are shown in Table 3. Two out of 37 patients treated with CapIri had local recurrence, four had metastatic disease, and two patients had both, local recurrence and metastatic disease. Thus, a total of 10.8% of patients had local recurrence and 16.2% had distant metastases, adding to an overall recurrence rate of 21.6%. Within the CapIri-cetuximab group the results were as follows: 10 out
Table 2: Pathohistological results of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/- cetuximab based chemoradiotherapy as preoperative treatment.

|                      | Capecitabine/irinotecan (n = 37) | Capecitabine/irinotecan + cetuximab (n = 49) | P value |
|----------------------|----------------------------------|-----------------------------------------------|---------|
| ypT downstaging, n (%) |                                  |                                               |         |
| ypT0                 | 7 (19)                           | 4 (8)                                         |         |
| ypT1                 | 5 (14)                           | 1 (2)                                         |         |
| ypT2                 | 11 (30)                          | 18 (37)                                       |         |
| ypT3                 | 12 (32)                          | 24 (49)                                       |         |
| ypT4                 | 2 (5)                            | 2 (4)                                         |         |
| Chi square           |                                  |                                               | 0.11    |
| ypN−                 | 23 (62)                          | 36 (73)                                       |         |
| ypN+                 | 14 (38)                          | 13 (27)                                       |         |
| Fisher’s exact test  |                                  |                                               | 0.35    |
| R0 resection, n (%)   | 36 (97)                          | 48 (98)                                       | 1.00    |
| Pathologic complete remission ypT0 pN0, n (%) | 7 (19) | 4 (8) |
| Fisher’s exact test  |                                  |                                               | 0.19    |
| T-downstaging (ypT0-2, pN0), n (%) | 9 (24) | 21 (43) |
| Fisher’s exact test  |                                  |                                               | 0.11    |

of 49 patients had distant failure (20.4%), and one patient had a local relapse (2.0%) adding to an overall recurrence rate of 22.4%.

Taken together, the 5-year DFS rate was 80% (82% for CapIri patients and 79% for CapIri-cetuximab patients; P = 0.62; Figure 1). The analysis of the cetuximab group according to KRAS status revealed a 5-year DFS of 84% for patients with KRAS WT and 74% for patients with KRAS mutation. This difference was not statistically significant (P = 0.71). Similarly, no significant difference in DFS was noticed between CapIri patients and patients with KRAS WT tumors receiving CapIri-cetuximab (P = 0.86).

The 5-year overall survival rate was 73%. The median overall survival for all patients was 127.4 months. No significant difference was seen between patients receiving CapIri or CapIri-cetuximab: 5-year overall survival was 73% for both groups (P = 0.61, Figure 2). A numerical difference was found regarding 5-year overall survival in patients treated with CapIri-cetuximab with respect to the KRAS mutational

Figure 1: Disease-free survival of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/- cetuximab based chemoradiotherapy as preoperative treatment (n = 86). Shown are survival curves of patients treated with CapIri (solid curve; n = 37) versus patients treated with CapIri + cetuximab (dotted curve; n = 49), P = 0.62.
status: 5-year overall survival rate was 78% for patients with KRAS WT tumors but only 62% for patients with tumors harboring KRAS mutations. However, no statistical significance was achieved ($P = 0.24$).

Similarly, no statistical significant difference between patients receiving CapIri and those receiving CapIri-cetuximab with KRAS WT tumors was noticed ($P = 0.39$; Figure 3).

4. Discussion

Neoadjuvant RCT or short-course radiotherapy followed by TME is a standard treatment for LARC [25, 26]. Although the local recurrence rate is generally below 10%, systemic recurrence still occurs in about 25–30% of cases [25, 26]. Thus far, alternative strategies using more intensive chemotherapeutic regimens and/or combination treatments with targeted agents failed to demonstrate a significant advantage over standard RCT [5–10, 14–17, 27–29]. Particularly, early efficacy endpoints, such as the pCR rate, could not be improved by addition of an anti-EGFR antibody to neoadjuvant RCT with capecitabine/5-FU alone or in combination with irinotecan or oxaliplatin [6–10, 14–17, 21].

Undoubtedly, patients achieving a pCR have an excellent long-term prognosis [30]. However, there is an ongoing debate if pCR may be used as a valid surrogate endpoint for rectal cancer trials [31]. In this regard, the results of EXPERT-C are of interest. A multicenter randomized phase II trial compared neoadjuvant oxaliplatin, capecitabine (CapOx), and preoperative radiotherapy with or without cetuximab in patients with high-risk LARC [11]. The trial was originally designed to detect a 20% improvement in pCR. The protocol was amended to the primary endpoint of complete response (pCR or radiologic complete response) in patients with KRAS/BRAF wild-type tumors. However, the primary endpoint “improved pathological complete response rate” or “radiologic complete response rate in patients with KRAS/BRAF WT tumors” was not met. The addition of cetuximab resulted in a significant increase in radiologic response and a clinically meaningful benefit in overall survival [11]. After longer follow-up, the difference remained still clinically significant with a 12% difference for 5-year overall survival (84.3% versus 72.3%). However, statistical significance could not be demonstrated anymore [19]. Likewise, the 5-year DFS was not statistically significantly different (75.4% versus 67.8%; $P = 0.23$).

The herein presented analysis is the first comparative data of long-term results of European patients with LARC receiving intensive neoadjuvant RCT with capecitabine and irinotecan with or without cetuximab within two sequential clinical trials. Although not randomized the patient population treated within these trials were well balanced, and inclusion criteria and staging measures for both studies were similar. Moreover, the patients were treated by the same multidisciplinary team within identical circumstances. Our findings indicate, comparable to the EXPERT-C experience, that the addition of cetuximab did not improve neither 5-year DFS nor OS. We observed only a small numerical 5-year survival benefit of 5% in favor of the KRAS WT patients receiving cetuximab compared to the (KRAS WT and mutated) CapIri patients (78% versus 73%; $P = 0.41$). Comparable to our results the analysis of two Korean trials using similar RCT regimens did not reveal a difference within the KRAS WT group [31]. The 5-year DFS rate in our patient population was virtually identical between the CapIri and the CapIri-cetuximab KRAS WT patients (84% and 82%,
It is noteworthy that in our series pCR rates were rather low within the cetuximab group by analogy with what has been observed in other trials like in the abovementioned EXPERT-C study. However, it is interesting that the rate of patients with ypT0-2 N0 tumors was higher in the cetuximab group (43% versus 24%), and the number of patients with pathological nodal negative disease was also higher in the cetuximab group (73% versus 62%) compared to the patients treated without cetuximab. It could be argued that cetuximab treated patients should undergo surgery after a longer period after completion of RCT. Indeed, range of time to resection was wider than planned in general but smaller in the cetuximab group compared to the patients treated without cetuximab. Moreover, the higher rate of cT2 tumors in favor of lower rates of cT3 and cT4 tumors in the cetuximab group could be a possible bias for the higher rate of ypT0-2 N0 downstaging in the cetuximab group. Someone may also speculate if tumor remission “beyond pCR” is something that is overlooked when focusing on pCR rate only. A similar observation has been made in the SAKK study which investigated the addition of panitumumab to a rate only. A similar observation has been made in the SAKK that something is overlooked when focusing on pCR rate only. A similar observation has been made in the SAKK study which investigated the addition of panitumumab to a capectabine-based RCT [21]. Using the regression grading described by Dworak and coworkers pCR rate was not increased by the addition of panitumumab. However, the rate of near-complete plus complete remissions was clearly higher (53% versus 32%). In this regard, it is noteworthy that the rate of local recurrences was rather small within the cetuximab group in our trial (one out of 49 patients after a follow-up of 72 months), while the rate of local recurrences within the chemotherapy without cetuximab group was higher (4 out of 37 patients after a follow-up of 105 months). Likewise, in the EXPERT-C trial the local recurrence rate in KRAS WT patients was numerically lower as well in the cetuximab group (5.4% versus 2.4% local relapse; hazard ratio 0.46, n.s.).

However, despite some hints of potential activity of cetuximab in the perioperative treatment of patients with LARC (i.e., numerical better survival rates, lower rates of local relapse, and indications for improved primary tumor shrinkage “beyond pCR”) the data at hand is not convincing so far. As recently reported, a benefit could not be demonstrated in RAS WT patients in the EXPERT-C trial. The explanation for the lack of activity is unclear. Among other arguments it has been speculated that cetuximab if delivered concurrently with radiation could potentially abolish additive effects of 5-FU, by inhibiting proliferation. Moreover preclinical data suggests that the sequencing of chemotherapy, EGFR inhibition, and radiation may be clinically significant. Additionally, it is known that cetuximab should not be combined with capecitabine in patients with metastatic colorectal cancer [33]. However, unfortunately most of the RCT/cetuximab trials in patients with LARC have been conducted using capecitabine.

In view of several negative studies with cetuximab based RCT, it seems unlikely that a definitive randomized phase III trial will be undertaken in LARC. However, lately it could be shown in the EXPERT-C study population that in patients with a TP 53 WT tumor the use of cetuximab in conjunction with RCT significantly improved the 5-year overall and disease-free survival (e.g., HR overall survival 0.16, 95% CI 0.04–0.70, and \( P = 0.02 \)). While TP53 status was not of prognostic value it emerged as a predictive factor for cetuximab benefit. The benefit from cetuximab in patients with TP53 wild-type tumors was independent of RAS [34]. Finally, there is currently no indication that anti-EGFR monoclonal antibodies, namely, cetuximab, should play a role in the perioperative treatment of all patients with locally advanced rectal cancer, not even of patients with (K)RAS WT tumors. Nevertheless, the recent findings that the TP53 WT status may serve as a strong predictor for cetuximab efficacy in the RCT of LARC may stimulate further retrospective and maybe prospective studies to elucidate treatment effects in smaller subgroups of patients.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**Authors’ Contribution**

K. Merx and R.-D. Hofheinz contributed equally to this work.

**References**

[1] D. Cunningham, W. Atkin, H.-J. Lenz et al., “Colorectal cancer,” The Lancet, vol. 375, no. 9719, pp. 1030–1047, 2010.
[2] J. Giralt, M. de Las Heras, L. Cerezo et al., “The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis,” Radiotherapy and Oncology, vol. 74, no. 2, pp. 101–108, 2005.
[3] J.-S. Kim, J.-M. Kim, S. Li et al., “Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 1, pp. 195–200, 2006.
[4] R. Kopp, E. Rothbauer, E. Mueller, F.W. Schildberg, K.-W. Jauch, and A. Pfeiffer, “Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels,” Diseases of the Colon and Rectum, vol. 46, no. 10, pp. 1391–1399, 2003.
[5] V. Velenik, J. Ocvirk, I. Oblak, and F. Anderluh, “A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer,” European Journal of Surgical Oncology, vol. 36, no. 3, pp. 244–250, 2010.
[6] F. Bertolini, S. Chiara, C. Bengala et al., “Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 2, pp. 466–472, 2009.
[7] J.-P. Machiels, C. Sempoux, P. Scalliet et al., “Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer,” Annals of Oncology, vol. 18, no. 4, pp. 738–744, 2007.
[8] C. Rödel, D. Arnold, M. Hipp et al., “Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer,” *International Journal of Radiation Oncology, Biology, Physics*, vol. 70, no. 4, pp. 1081–1086, 2008.

[9] K. Horisberger, A. Treschl, S. Mai et al., “Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial,” *International Journal of Radiation Oncology Biology Physics*, vol. 74, no. 5, pp. 1487–1493, 2009.

[10] S. Y. Kim, Y. S. Hong, D. Y. Kim et al., “Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study,” *International Journal of Radiation Oncology Biology Physics*, vol. 81, no. 3, pp. 677–683, 2011.

[11] A. Dewdney, D. Cunningham, J. Tabernero et al., “Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C),” *Journal of Clinical Oncology*, vol. 30, no. 14, pp. 1620–1627, 2012.

[12] E. van Cutsem, C.-H. Köhne, I. Láng et al., “Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status,” *Journal of Clinical Oncology*, vol. 29, no. 15, pp. 2011–2019, 2011.

[13] S. Stintzing, A. Jung, L. Rossius et al., “Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3—a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients,” *Journal of Clinical Oncology*, vol. 32, supplement 3, 2014, Gastrointestinal Cancers Symposium, Abstract 445.

[14] C. Weiss, D. Arnold, K. Dellas et al., “Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials,” *International Journal of Radiation Oncology Biology Physics*, vol. 78, no. 2, pp. 472–478, 2010.

[15] P.-L. Sun, B. Li, and Q.-F. Ye, “Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study,” *International Journal of Colorectal Disease*, vol. 27, no. 10, pp. 1325–1332, 2012.

[16] V. Velenik, J. Ovcirk, I. Oblak, and F. Anderlhu, “Cetuximab in preoperative treatment of rectal cancer—term outcome of the XERT trial,” *Radiology and Oncology*, vol. 46, no. 3, pp. 252–257, 2012.

[17] A. Debuquoy, K. Haustermans, A. Daemen et al., “Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer,” *Journal of Clinical Oncology*, vol. 27, no. 17, pp. 2751–2757, 2009.

[18] E. Fokas, L. Conradi, C. Weiss et al., “Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase I/2 study,” *International Journal of Radiation Oncology Biology Physics*, vol. 87, no. 5, pp. 992–999, 2013.

[19] F. Sclafani, D. Gonzalez, D. Cunningham et al., “RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial,” *European Journal of Cancer*, vol. 50, no. 8, pp. 1430–1436, 2014.

[20] O. Dworak, L. Keilholz, and A. Hoffmann, “Pathological features of rectal cancer after preoperative radiochemotherapy,” *International Journal of Colorectal Disease*, vol. 12, no. 1, pp. 19–23, 1997.

[21] D. Hellbing, G. Bodoky, O. Gautschi et al., “Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07,” *Annals of Oncology*, vol. 24, no. 3, pp. 718–725, 2013.

[22] F. Willeke, K. Horisberger, U. Kraus-Tiefenbacher et al., “A phase II study of cetuximab and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer,” *British Journal of Cancer*, vol. 96, no. 6, pp. 912–917, 2007.

[23] R.-D. Hofheinz, B. von Gerstenberg-Heldorf, F. Wenz et al., “Phase I trial of cetuximab and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer,” *Journal of Clinical Oncology*, vol. 23, no. 7, pp. 1350–1357, 2005.

[24] P. Erben, P. Ströbel, K. Horisberger et al., “KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer,” *International Journal of Radiation Oncology Biology Physics*, vol. 81, no. 4, pp. 1032–1038, 2011.

[25] W. van Gijn, C. A. Marijnen, I. D. Nagtegaal et al., “Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial,” *The Lancet Oncology*, vol. 12, no. 6, pp. 575–582, 2011.

[26] R. Sauer, T. Liersch, S. Merkel et al., “Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years,” *Journal of Clinical Oncology*, vol. 30, no. 16, pp. 1926–1933, 2012.

[27] C. Aschele, L. Cionini, S. Lonardi et al., “Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial,” *Journal of Clinical Oncology*, vol. 29, no. 20, pp. 2773–2780, 2011.

[28] J.-P. Gérard, D. Azria, S. Gourgou-Bourgade et al., “Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer,” *Journal of Clinical Oncology*, vol. 30, no. 36, pp. 4558–4565, 2012.

[29] C. Rödel, T. Liersch, H. Becker et al., “Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial,” *The Lancet Oncology*, vol. 13, no. 7, pp. 679–687, 2012.

[30] S. T. Martin, H. M. Heneghan, and D. C. Winter, “Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer,” *British Journal of Surgery*, vol. 99, no. 7, pp. 918–928, 2012.

[31] F. Bonnetain, J. F. Bosset, J. P. Gerard et al., “What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3–4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?” *European Journal of Cancer*, vol. 48, no. 12, pp. 1781–1790, 2012.

[32] S. Y. Kim, E. K. Shim, H. Y. Yeo et al., “KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials,” *International Journal of Radiation Oncology Biology Physics*, vol. 85, no. 1, pp. 201–207, 2013.
[33] G. Y. Ku, B. A. Haaland, and G. de Lima Lopes Jr., “Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters,” *Cancer Chemotherapy and Pharmacology*, vol. 70, no. 2, pp. 231-238, 2012.

[34] F. Sclafani, D. Gonzalez, D. Cunningham et al., “TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial,” *Journal of the National Cancer Institute*, vol. 106, no. 7, 2014.